<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03912285</url>
  </required_header>
  <id_info>
    <org_study_id>HM-ALOS-101</org_study_id>
    <nct_id>NCT03912285</nct_id>
  </id_info>
  <brief_title>The Pharmacokinetic Interaction Between Amlodipine and Losartan</brief_title>
  <official_title>Pharmacokinetic and Hemodynamic Interactions Between Amlodipine and Losartan in Humans</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Korea University Anam Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Hanmi Pharmaceutical co., ltd.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Korea University Anam Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This clinical trial aims to assess the pharmacokinetic interaction between amlodipine and
      losartan in healthy male subjects.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 10, 2008</start_date>
  <completion_date type="Actual">June 9, 2009</completion_date>
  <primary_completion_date type="Actual">March 17, 2009</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>an open-label, three-period, fixed-sequence clinical trial</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>AUCtau(area under the plasma concentration-time curve for a dosing interval at steady state)</measure>
    <time_frame>0 (predose) ~ 24 hours at day 9, day 31, and day 46</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax,ss(Maximum plasma concentration of the drug at steady state)</measure>
    <time_frame>0 (predose) ~ 24 hours at day 9, day 31, and day 46</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cmin,ss(Minimum concentration of the drug in plasma at steady state)</measure>
    <time_frame>0 (predose) ~ 24 hours at day 9, day 31, and day 46</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tmax,ss(Time to maximum plasma concentration at steady state)</measure>
    <time_frame>0 (predose) ~ 24 hours at day 9, day 31, and day 46</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>1/2(Terminal elimination half-life)</measure>
    <time_frame>0 (predose) ~ 24 hours at day 9, day 31, and day 46</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CLss/F(Apparent total body clearance of the drug from plasma at steady state)</measure>
    <time_frame>0 (predose) ~ 24 hours at day 9, day 31, and day 46</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vd,ss/F(Apparent volume of distribution at steady state)</measure>
    <time_frame>0 (predose) ~ 24 hours at day 9, day 31, and day 46</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PTF(Peak-to-trough fluctuation)</measure>
    <time_frame>0 (predose) ~ 24 hours at day 9, day 31, and day 46</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Amlodipine, losartan, and amlodipine plus losartan</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Period 1:
amlodipine 10mg will be administered orally once a day for 9 days.
Period 2:
losartan 100mg will be administered orally once a day for 9 days after 13 days of the washout period.
Period 3:
amlodipine 10mg once a day plus losartan 100mg once a day will be administered orally for 9 days after 6 days of the washout period.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Amlodipine10mg</intervention_name>
    <description>Amlodipine 10mg will be administered orally twice a day for 9 days</description>
    <arm_group_label>Amlodipine, losartan, and amlodipine plus losartan</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Losartan potassium 100mg</intervention_name>
    <description>Losartan 100mg will be administered orally once a day for 9 days</description>
    <arm_group_label>Amlodipine, losartan, and amlodipine plus losartan</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Amlodipine plus Losartan</intervention_name>
    <description>Amlodipine plus Losartan same way as &quot;arm: amlodipine&quot; and &quot;arm: losartan&quot;</description>
    <arm_group_label>Amlodipine, losartan, and amlodipine plus losartan</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Healthy volunteers aged between ≥ 20 and ≤ 45 years old

          2. Weight ≥ 50kg, with calculated body mass index(BMI) of ≥ 18 and ≤ 29.9kg/m²

          3. Subjects who agree to use a combination of effective contraceptive methods or
             medically acceptable contraceptive methods for up to 28 days after the date of
             administration of the clinical trial drug and agree not to provide sperm

          4. Subject who are informed of the investigational nature of this study, voluntarily
             agree to participate in this study

        Exclusion Criteria:

          1. History or presence of a clinically significant and active cardiovascular,
             respiratory, hepatobiliary, renal, hematological, gastrointestinal, endocrine, immune,
             dermatologic, neurologic or psychiatric disorder

          2. With symptoms indicating acute illness within 28 days prior to the first
             Investigational Product administration

          3. Any medical history that may affect drug absorption, distribution, metabolism, and
             excretion

          4. Genetic problems such as galactose intolerance, Lapp lactose dehydrogenase deficiency
             or glucose-galactose uptake disorder

          5. Any clinically significant active chronic disease
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Dept. of Clinical Pharmacology &amp; Toxicology, Anam Hospital, Korea University College of Medicine</name>
      <address>
        <city>Seoul</city>
        <zip>136-705</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>April 2019</verification_date>
  <study_first_submitted>April 9, 2019</study_first_submitted>
  <study_first_submitted_qc>April 9, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">April 11, 2019</study_first_posted>
  <last_update_submitted>April 10, 2019</last_update_submitted>
  <last_update_submitted_qc>April 10, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">April 12, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Korea University Anam Hospital</investigator_affiliation>
    <investigator_full_name>Ji-Young Park</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Losartan</mesh_term>
    <mesh_term>Amlodipine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

